MX2023012793A - Métodos y composiciones para el tratamiento de la retinopatía diabética y condiciones relacionadas. - Google Patents
Métodos y composiciones para el tratamiento de la retinopatía diabética y condiciones relacionadas.Info
- Publication number
- MX2023012793A MX2023012793A MX2023012793A MX2023012793A MX2023012793A MX 2023012793 A MX2023012793 A MX 2023012793A MX 2023012793 A MX2023012793 A MX 2023012793A MX 2023012793 A MX2023012793 A MX 2023012793A MX 2023012793 A MX2023012793 A MX 2023012793A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- diabetic retinopathy
- methods
- treatment
- related conditions
- Prior art date
Links
- 206010012689 Diabetic retinopathy Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 206010012688 Diabetic retinal oedema Diseases 0.000 abstract 1
- 208000017442 Retinal disease Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000011190 diabetic macular edema Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163182037P | 2021-04-30 | 2021-04-30 | |
| PCT/US2022/027062 WO2022232597A1 (en) | 2021-04-30 | 2022-04-29 | Methods and compositions for treatment of diabetic retinopathy and related conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023012793A true MX2023012793A (es) | 2024-01-11 |
Family
ID=83848745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023012793A MX2023012793A (es) | 2021-04-30 | 2022-04-29 | Métodos y composiciones para el tratamiento de la retinopatía diabética y condiciones relacionadas. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240216315A1 (enExample) |
| EP (1) | EP4329741A4 (enExample) |
| JP (1) | JP2024516003A (enExample) |
| KR (1) | KR20240049212A (enExample) |
| CN (1) | CN117500492A (enExample) |
| AU (1) | AU2022264037A1 (enExample) |
| BR (1) | BR112023022561A2 (enExample) |
| CA (1) | CA3217136A1 (enExample) |
| IL (1) | IL308083A (enExample) |
| MX (1) | MX2023012793A (enExample) |
| WO (1) | WO2022232597A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025529483A (ja) | 2022-09-14 | 2025-09-04 | オーパス・ジェネティクス・インコーポレイテッド | Ａｐｘ３３３０の塩及びエステルならびにその治療的使用 |
| WO2024158972A1 (en) * | 2023-01-25 | 2024-08-02 | Ocuphire Pharma, Inc. | Methods and compositions for preventing the progression of diabetic retinopathy and related conditions |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0817293A2 (pt) * | 2007-09-26 | 2015-06-16 | Univ Indiana Res & Tech Corp | Derivado de benzoquinona e3330 em combinação com agentes quimioterapêuticos para o tratamento de câncer e angiogenese |
| CA3090766A1 (en) * | 2018-02-08 | 2019-08-15 | Indiana University Research And Technology Corporation | Targeting ocular diseases with novel ape1/ref-1 inhibitors |
-
2022
- 2022-04-29 JP JP2023566803A patent/JP2024516003A/ja active Pending
- 2022-04-29 CA CA3217136A patent/CA3217136A1/en active Pending
- 2022-04-29 AU AU2022264037A patent/AU2022264037A1/en active Pending
- 2022-04-29 IL IL308083A patent/IL308083A/en unknown
- 2022-04-29 MX MX2023012793A patent/MX2023012793A/es unknown
- 2022-04-29 WO PCT/US2022/027062 patent/WO2022232597A1/en not_active Ceased
- 2022-04-29 US US18/288,435 patent/US20240216315A1/en active Pending
- 2022-04-29 EP EP22796862.5A patent/EP4329741A4/en active Pending
- 2022-04-29 BR BR112023022561A patent/BR112023022561A2/pt unknown
- 2022-04-29 KR KR1020237041163A patent/KR20240049212A/ko active Pending
- 2022-04-29 CN CN202280038694.0A patent/CN117500492A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022232597A1 (en) | 2022-11-03 |
| JP2024516003A (ja) | 2024-04-11 |
| BR112023022561A2 (pt) | 2024-01-02 |
| US20240216315A1 (en) | 2024-07-04 |
| KR20240049212A (ko) | 2024-04-16 |
| EP4329741A1 (en) | 2024-03-06 |
| CA3217136A1 (en) | 2022-11-03 |
| IL308083A (en) | 2023-12-01 |
| EP4329741A4 (en) | 2025-01-08 |
| AU2022264037A1 (en) | 2023-11-16 |
| CN117500492A (zh) | 2024-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| De Keyser et al. | Selective laser trabeculoplasty as replacement therapy in medically controlled glaucoma patients | |
| EP4491229A3 (en) | Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases | |
| MX2020003534A (es) | Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares. | |
| BR0317774A (pt) | Uso de rimexolona no tratamento de olho seco | |
| MX2020009132A (es) | Composiciones farmaceuticas que comprenden nebivolol. | |
| MX2022011697A (es) | Inhibidores de ciclofilina y usos de los mismos. | |
| MX2021015338A (es) | Composicion que comprende pridopidina y un analogo de la misma para el tratamiento de la enfermedad de huntington y sintomas de la misma. | |
| BR112021017436A2 (pt) | Composições farmacêuticas para tratamento de doenças ou transtornos oculares | |
| MX2019013799A (es) | Peptido novedoso y composicion farmaceutica para tratar una enfermedad ocular que comprende el mismo como un ingrediente farmaceutico activo. | |
| BR112022020441A2 (pt) | Composições compreendendo nanopartículas, método de fabricação e usos das mesmas | |
| JOP20230133A1 (ar) | استخدام منشطات sGC لمعالجة الأمراض العينية | |
| BR112023022561A2 (pt) | Métodos e composições para o tratamento de retinopatia diabética e condições relacionadas | |
| PH12020551015A1 (en) | Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability | |
| BR112023018932A2 (pt) | Formulação para administração ocular, recipiente de dosagem, uso de uma formulação, e, método para o tratamento de um transtorno ocular | |
| MX2023004539A (es) | Compuestos y metodos para el tratamiento de trastornos oculares. | |
| CL2020001426A1 (es) | Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo. | |
| CO2025015464A2 (es) | Implante ocular que comprende el polimorfo iv de axitinib | |
| MX2023010918A (es) | Metodos y composiciones para el tratamiento de enfermedades oculares. | |
| JP2015522601A5 (enExample) | ||
| RU95104837A (ru) | Способ хирургического лечения отслойки сетчатки, осложненной пролиферативной витреоретинопатией | |
| MX2022010437A (es) | Tratamiento mejorado de la dermatitis atopica con tradipitant. | |
| Khalaf et al. | Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution | |
| EA202000298A1 (ru) | ПРОТИВОКОРОНАВИРУСНОЕ СРЕДСТВО ДЛЯ КОМБИНИРОВАННОЙ ТЕРАПИИ COVID-19 (SARS-CoV-2) И СПОСОБ ЛЕЧЕНИЯ | |
| EA202000299A1 (ru) | ПРОТИВОКОРОНАВИРУСНОЕ СРЕДСТВО ДЛЯ КОМБИНИРОВАННОЙ ТЕРАПИИ COVID-19 (SARS-CoV-2) | |
| CL2024003968A1 (es) | Triazoles para su uso en el tratamiento de enfermedades oculares. |